Cardiovascular (CV) Risk Evaluation In Type 2 Diabetes Subjects

GlaxoSmithKline1,100 enrolled

Overview

The primary objective of this study is to assess the total CV risk in patients with type 2 diabetes and also to assess the impact of rosiglitazone in the total CV risk and the parameters of metabolic syndrome.

Study Type

OBSERVATIONAL

Enrollment

1,100

Conditions

Type 2 Diabetes Mellitus CV Risk

Eligibility

Sex: ALLMin age: 40 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion criteria: * Patients with diabetes type 2 that their physician has decided to prescribe AVANDIA for better control of their condition * Have signed informed consent Exclusion Criteria: * Patients with ALT \> 2.5x the normal value * With heart failure symptoms * With diagnosis of angina pectoris or stable angina demanding continuous treatment with nitrates * With recent myocardial infarction (\<6 months) * With severe renal disfunction * Pregnant or lactating or planned to be pregnant during the study * Under investigational drug treatment * Alcoholic or drug abuser

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.